Company intelligence / Profile preview

Enimmune

Ownership: Private
Development stage: Phase 1

Overview

Enimmune has advanced its lead enterovirus 71 vaccine candidate ("EnVAX-A71") through Phase III and submitted NDAs in Taiwan and Macau. The company also markets approved diagnostic products such as the Tuberculin PPD RT23 SSI for tuberculosis testing and COVID antigen rapid tests. It is developing additional vaccines targeting pneumonia, norovirus, dengue fever virus, and MERS-CoV.

Therapeutic areas: Infectious Diseases
Modalities: VaccineMonoclonal antibodySmall molecule
Industry: Biotech

Drug pipeline

1 asset

envax-a71

Partnerships

AIOS BIOTECH PTE. LTD. (Singapore) – joint venture partnerAbcombi Biosciences Inc. – pneumococcal vaccine development partnerSK Bioscience Co., Ltd., VISIONMED Co., Ltd., Inibio Co., Ltd. – exclusive distribution agreements in South Korea

Beyond the preview

Go deeper on Enimmune.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enimmune.

Explore the full profile